Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. As a science-driven biopharmaceutical company, we are focused on developing medicines that will have a meaningful impact on patients’ lives. We are excited to have both a Marketing Authorization Application (MAA) in Europe and a New Drug Application (NDA) in the United States under regulatory review for the investigational drug, abaloparatide for subcutaneous administration, for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Also in development is the investigational abaloparatide transdermal patch for potential use in osteoporosis. Additionally, we have the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, as well as vasomotor symptoms in postmenopausal women. Our preclinical pipeline includes the early stage candidate, RAD140, a non-steroidal, selective androgen receptor modulator for potential use in multiple applications. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.
Key People at Radius Health
Michael Wyzga
Gary Hattersley
Michael Franken
Radius Health Office Locations
Radius Health Data and Metrics
Radius Health Financial Metrics
Net income (FY, 2015) | (101.5 m) |
EBIT (FY, 2015) | (99.1 m) |
Market capitalization (25-May-2017) | 1.6 b |
Closing share price (25-May-2017) | 37.4 |
Cash (31-Dec-2016) | 258.6 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
EBIT | (67.4 m) | (59.4 m) | (99.1 m) |
Net Income | (60.7 m) | (62.5 m) | (101.5 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 12.3 m | 258.6 m | ||
Inventories | 334 k | 2.3 m | ||
Current Assets | 12.6 m | 334.8 m | ||
PP&E | 76 k | 4.9 m | ||
Total Assets | 12.8 m | 340.3 m | ||
Accounts Payable | 300 k | 6.1 m | ||
Current Liabilities | 35.3 m | 32.7 m | ||
Preferred Stock | 43.9 m | |||
Additional Paid-in Capital | 935.7 m | |||
Retained Earnings | (277.3 m) | (628.6 m) | ||
Total Equity | (277.3 m) | 307.2 m | ||
Financial Leverage | 0 x | 1.1 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (60.7 m) | (101.5 m) | (182.8 m) | |
Depreciation and Amortization | 27 k | 586 k | ||
Inventories | 1.7 m | 2.1 m | 7 m | 4.6 m |
Accounts Payable | (250 k) | 2.3 m | 6.2 m | (100 k) |
Cash From Operating Activities | (45 m) | 16.2 m | 131.2 m | (139.8 m) |
Purchases of PP&E | (2 k) | (2.9 m) | ||
Cash From Investing Activities | 4 m | 236.1 m | ||
Cash From Financing Activities | 34.7 m | 2.6 m | ||
Interest Paid | 1.8 m |
| Y, 2016 | |
|---|---|
Financial Leverage | 1.1 x |
